Elevance Health Appoints Nathan Rich Vice President, Investor Relations
Elevance Health (NYSE: ELV) has appointed Nathan Rich as Vice President of Investor Relations, effective November 11, 2024. Rich will lead the company's investor relations efforts and join the executive leadership team, reporting to CFO Mark Kaye. He succeeds Stephen Tanal, who transitions to CFO of Elevance Health's Government Health Benefits business. Rich brings nearly two decades of experience, previously serving as VP in Global Investment Research at Goldman Sachs and as a sell-side research analyst at Citi.
Elevance Health (NYSE: ELV) ha nominato Nathan Rich come Vice Presidente delle Relazioni con gli Investitori, con effetto dall'11 novembre 2024. Rich guiderà gli sforzi di relazioni con gli investitori dell'azienda e si unirà al team di leadership esecutiva, riportando al CFO Mark Kaye. Sostituisce Stephen Tanal, che passa a CFO del business dei Benefici Sanitari del Governo di Elevance Health. Rich porta con sé quasi vent'anni di esperienza, avendo precedentemente ricoperto il ruolo di VP nella Ricerca sugli Investimenti Globali presso Goldman Sachs e come analista di ricerca sell-side presso Citi.
Elevance Health (NYSE: ELV) ha nombrado a Nathan Rich como Vicepresidente de Relaciones con Inversores, con efecto a partir del 11 de noviembre de 2024. Rich encabezará los esfuerzos de relaciones con inversores de la empresa y se unirá al equipo de liderazgo ejecutivo, reportando al CFO Mark Kaye. Sucede a Stephen Tanal, quien hace la transición a CFO del negocio de Beneficios de Salud del Gobierno de Elevance Health. Rich aporta casi dos décadas de experiencia, habiendo servido anteriormente como VP en Investigación Global de Inversiones en Goldman Sachs y como analista de investigación del lado de la venta en Citi.
엘리반스 헬스 (NYSE: ELV)가 네이선 리치를 투자자 관계 부사장으로 임명했습니다. 임기는 2024년 11월 11일부터 시작됩니다. 리치는 회사의 투자자 관계 노력을 이끌고 경영 리더십 팀에 합류하여 CFO 마크 케이에게 보고합니다. 그는 엘리반스 헬스의 정부 건강 혜택 사업의 CFO로 전환하는 스티븐 타날을 대신합니다. 리치는 거의 20년의 경력을 가지고 있으며, 이전에는 골드만 삭스에서 글로벌 투자 연구 부사장으로, 시티에서 매도측 리서치 분석가로 근무했습니다.
Elevance Health (NYSE: ELV) a nommé Nathan Rich au poste de Vice-Président des Relations avec les Investisseurs, à compter du 11 novembre 2024. Rich dirigera les efforts de relations avec les investisseurs de l'entreprise et rejoindra l'équipe de direction exécutive, relevant du CFO Mark Kaye. Il succède à Stephen Tanal, qui passe au poste de CFO de l'activité des Avantages de Santé Gouvernementaux d'Elevance Health. Rich apporte près de deux décennies d'expérience, ayant précédemment exercé comme VP en Recherche d'Investissements Globale chez Goldman Sachs et en tant qu'analyste de recherche côté vente chez Citi.
Elevance Health (NYSE: ELV) hat Nathan Rich zum Vice President für Investor Relations ernannt, mit Wirkung zum 11. November 2024. Rich wird die Investorenbeziehungen des Unternehmens leiten und dem Führungsteam beitreten, wobei er an CFO Mark Kaye berichtet. Er folgt auf Stephen Tanal, der zum CFO des Geschäftsbereichs Regierungs-Gesundheitsleistungen von Elevance Health wechselt. Rich bringt fast zwei Jahrzehnte Erfahrung mit, zuvor war er VP in der globalen Investmentforschung bei Goldman Sachs und als Research Analyst im Verkaufsteam bei Citi tätig.
- Strategic leadership addition with extensive industry experience
- Internal promotion for previous IR head to CFO position shows strong succession planning
- Strengthening of executive team with experienced Wall Street professional
- None.
“Nate brings nearly two decades of experience spanning multiple sectors, including managed care, healthcare services, and consumer industries,” said Mark Kaye. “His diverse expertise, coupled with his analytical acumen will be instrumental in driving our strategy forward as we continue to evolve as a lifetime trusted health partner.”
Prior to joining Elevance Health, Mr. Rich served as Vice President in Global Investment Research at Goldman Sachs. He also held roles of increasing responsibility at Citi as a sell-side research analyst.
Mr. Rich holds a Bachelor of Science degree, magna cum laude, from New York University’s Leonard N. Stern School of Business.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241103351599/en/
Media Contact:
Leslie Porras
Leslie.Porras@ElevanceHealth.com
Investor Relations:
Investor.Relations@elevancehealth.com
Source: Elevance Health, Inc.
FAQ
When will Nathan Rich start as VP of Investor Relations at Elevance Health (ELV)?
Who did Nathan Rich replace as VP of Investor Relations at Elevance Health (ELV)?
What was Nathan Rich's previous position before joining Elevance Health (ELV)?
